Fortune: These Drug Companies Are Best Positioned to Fight a ‘Superbug’

This article by Chris Morris for Fortune cites the Antimicrobial Resistance Benchmark to argue which pharmaceutical companies are best prepared to respond to the rise of antibiotic resistant "superbugs."

Christ writes: "Viruses are getting a lot stronger and antibiotics aren’t always as effective as they used to be. That has led the World Health Organization to label antibiotic resistance a “global health emergency.” In response, the Access to Medicine Foundation published an index that ranks which drug companies are best positioned to face the threat.

"GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) led the list, which was released Tuesday at the World Economic Forum in Davos, Switzerland. Among generic drug companies, Mylan (MYL) led the pack and among biotechnology companies, Entasis came out on top."